Reported Friday, BridgeBio's Attruby Earns FDA Nod As First Therapy With ≥90% TTR Stabilization, Offering Hope For ATTR-CM Patients

BenzingaNov 25 02:31 ET

BridgeBio Pharma Up Over 16%, on Pace for Largest Percent Increase Since July 2023 -- Data Talk

Dow Jones14:41 ET

Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY (Acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis

PR Newswire14:30 ET

Sector Update: Health Care Stocks Rise in Monday Afternoon Trading

MT Newswires13:45 ET

Sector Update: Health Care

MT Newswires13:34 ET

Unusual Options Activity: VFC, MTCH and Others Attract Market Bets, VFC V/OI Ratio Reaches 333.3

Moomoo News13:30 ET